On March 28, 2024, Tonix Pharmaceuticals Holding Corp. announced the entry into a securities purchase agreement with certain institutional investors. The agreement includes the sale and issuance of approximately 10.8 million shares of common stock, pre-funded warrants to purchase up to 3.9 million shares, and Series E warrants to purchase up to 14.7 million shares. The offering price per share and accompanying Series E Warrant is $0.30, and for Pre-Funded Warrant and accompanying Series E Warrant is $0.2999. The Pre-Funded Warrants are immediately exercisable at $0.0001 per share, while the Series E Warrants have an exercise price of $0.33 per share, exercisable six months after issuance and expiring five and a half years from the date of issuance. The offering is expected to generate gross proceeds...Show More

On March 28, 2024, Tonix Pharmaceuticals Holding Corp. announced the entry into a securities purchase agreement with certain institutional investors. The agreement includes the sale and issuance of approximately 10.8 million shares of common stock, pre-funded warrants to purchase up to 3.9 million shares, and Series E warrants to purchase up to 14.7 million shares. The offering price per share and accompanying Series E Warrant is $0.30, and for Pre-Funded Warrant and accompanying Series E Warrant is $0.2999. The Pre-Funded Warrants are immediately exercisable at $0.0001 per share, while the Series E Warrants have an exercise price of $0.33 per share, exercisable six months after issuance and expiring five and a half years from the date of issuance. The offering is expected to generate gross proceeds of approximately $4.4 million, which the company plans to use for working capital, general corporate purposes, and to satisfy a portion of its existing debt. The company has also entered into a placement agent agreement with A.G.P./Alliance Global Partners, who will arrange for the sale of the securities. Tonix Pharmaceuticals will pay the placement agent a cash fee of 7.0% of the aggregate purchase price and reimburse up to $100,000 for expenses. Additionally, the company has agreed to a 60-day prohibition on issuing or announcing the issuance of any common stock or securities convertible into common stock, with certain exceptions. Directors and officers of the company have also agreed to a 90-day lock-up period for their securities. Furthermore, the company will amend the exercise price and expiration date of certain existing warrants, subject to stockholder approval. If approval is not obtained by October 1, 2024, the exercise price will be adjusted to the Nasdaq minimum price. The offering is made under a registration statement on Form S-3, declared effective by the SEC on August 26, 2022, and supplemented by a prospectus supplement dated March 28, 2024.